Epikast

Name: Epikast
Brand: Epikast

AI Native

Epikast is a life-sciences services and technology provider that supplies medically credentialed commercial and medical-affairs personnel and AI-supported engagement and analytics tools to enable hybrid stakeholder coverage and reduce operational costs.

Est 2022|Valuation $37.2M|Raised $11.5M

LinkedIn 953|Website|FTEs 60|HQ New York, NY

Published Sep 19, 2026

01Common complaints

Choose alternatives or build internally when:

You require audited security attestations (for example, SOC 2 Type II or ISO 27001) as a gating factor and Epikast cannot provide them promptly under NDA.
You need global, 24/7, high-volume contact center operations with extensive language coverage and long operational track records—large incumbents may be preferable.
You require a mature standalone SaaS platform with broad ecosystem integrations and a large admin community (Epikast appears to be services-led with proprietary AI components rather than a widely reviewed SaaS platform).
Your procurement or compliance process requires extensive, named-brand public case studies and a substantial third-party customer review footprint—public proof is limited.
You need guaranteed large-scale surge capacity across many therapeutic areas simultaneously; larger vendors may provide deeper bench strength.

Red flags to watch in buying:

Reliance on percentage-savings claims in the absence of transparent baselines
Ambiguous descriptions of the vendor’s AI capabilities, data sources, and validation or governance practices

Choose alternatives or build internally when: 1. You require audited security attestations (for example, SOC 2 Type II or ISO 27001) as a gating factor and Epikast cannot provide them promptly under NDA. 2. You need global, 24/7, high-volume contact center operations with extensive language coverage and long operational track records—large incumbents may be preferable. 3. You require a mature standalone SaaS platform with broad ecosystem integrations and a large admin community (Epikast appears to be services-led with proprietary AI components rather than a widely reviewed SaaS platform). 4. Your procurement or compliance process requires extensive, named-brand public case studies and a substantial third-party customer review footprint—public proof is limited. 5. You need guaranteed large-scale surge capacity across many therapeutic areas simultaneously; larger vendors may provide deeper bench strength. Red flags to watch in buying: - Reliance on percentage-savings claims in the absence of transparent baselines - Ambiguous descriptions of the vendor’s AI capabilities, data sources, and validation or governance practices

Vendor-acknowledged limitations

The vendor does not publish explicit limitations, uptime commitments, or a public product roadmap.

Practical limitations (based on available evidence)

Limited public transparency into the proprietary AI tooling, including capabilities, evaluation metrics, and governance or bias-mitigation practices
Security posture is not fully evidenced via public attestations
Low public customer review footprint, reducing the ability to validate service quality at scale

Organizational maturity risk

Employee reviews show mixed sentiment; the vendor’s small scale (estimated 11–50 employees) may constrain concurrent large deployments.

Sources:

Employee reviews show mixed sentiment; the vendor’s small scale (estimated 11–50 employees) may constrain concurrent large deployments. Sources: - https://www.glassdoor.com/Reviews/Epikast-Reviews-E9323401.htm - https://www.crunchbase.com/organization/epikast-inc

02Why they buy

Unique selling points with supporting evidence

Medically credentialed staffing model: The vendor emphasizes MD/PhD-level and clinically experienced personnel for scientific engagement.
Combination of services and AI-supported insights: The vendor describes internal tooling intended to support engagement and insight generation, though public details on the tooling’s capabilities and validation are limited.
Operational presence in Greece: The vendor states it maintains a hub in Greece that it uses to scale personnel for US and European programs.

Sources:

- Medically credentialed staffing model: The vendor emphasizes MD/PhD-level and clinically experienced personnel for scientific engagement. - Combination of services and AI-supported insights: The vendor describes internal tooling intended to support engagement and insight generation, though public details on the tooling’s capabilities and validation are limited. - Operational presence in Greece: The vendor states it maintains a hub in Greece that it uses to scale personnel for US and European programs. Sources: - https://epikast.com/ - https://www.epikast.com/medical-affairs.html - https://fiercepharmaengage25.smallworldlabs.com/co/epikast-inc

Where competitors may have stronger unique selling points

Larger incumbents typically maintain more extensive public case-study libraries, broader compliance infrastructures, and integrated multi-service delivery capabilities.

03Field reports

Review-platform presence (G2, Capterra, TrustRadius)

Epikast does not appear to have an established product listing with customer reviews on major B2B software review platforms based on searches for those platforms. This may reflect the vendor’s positioning as a services firm with proprietary tools rather than a standalone SaaS product.

Implication: Prospective buyers will have fewer third-party customer reviews to consult and should prioritize reference checks, pilots, and contractual service-level agreements.

Community / social proof

Public community discussions (Reddit, Hacker News) about Epikast were not identified in searches performed, which suggests limited public discourse or possible name ambiguity.

The vendor has some industry visibility through event listings and association membership.

Employee reviews (Glassdoor) — signal, not customer feedback

Employee-review sites contain a limited review volume. These items can provide directional signals about operations, leadership, and organizational maturity.

Examples of negative sentiment (paraphrased):

Concerns about professionalism and leadership direction.
Reports of unclear management and lack of direction.

Examples of positive sentiment (paraphrased):

Positive comments about learning opportunities and an open-minded culture.
References to an interesting AI product and potential benefits.

Important caveats:

Some employee-review content may include references unrelated to operational performance; treat employee-review content as non-validated signals requiring further due diligence.

Employee-review sites contain a limited review volume. These items can provide directional signals about operations, leadership, and organizational maturity. Examples of negative sentiment (paraphrased): - Concerns about professionalism and leadership direction. - Reports of unclear management and lack of direction. Examples of positive sentiment (paraphrased): - Positive comments about learning opportunities and an open-minded culture. - References to an interesting AI product and potential benefits. Important caveats: - Some employee-review content may include references unrelated to operational performance; treat employee-review content as non-validated signals requiring further due diligence.

Why customers might select Epikast (inferred from positioning)

Need to scale scientifically trained or clinically experienced talent quickly (MSLs, reimbursement specialists)
Preference for a hybrid (remote plus in-person) engagement model to address HCP access and coverage constraints
Intention to reduce fixed field-force costs by using flexible staffing models

Why customers might avoid or churn (inferred risks)

Limited independent evidence supporting the vendor’s cost-savings claims
Limited third-party customer review footprint, making quality validation more difficult
Early-stage vendor maturity risks (processes, scalability, staffing continuity)

Public case studies availability

No detailed public case studies with quantified outcomes were identified on Epikast’s website during searches for case-study materials.

Vendor-published outcomes and methodology gaps

Epikast publishes outcome-oriented claims (for example, cost-savings and time-to-launch statements), but the site does not provide:

Methodology (baseline costs, included/excluded items)
Sample size or number of programs supporting the figures
Customer names tied to reported metrics

Recommendation: buyers should request:

At least two to three customer references in similar therapeutic areas
A sample KPI dashboard and engagement reporting pack
A redacted SOW example and staffing plan

Epikast publishes outcome-oriented claims (for example, cost-savings and time-to-launch statements), but the site does not provide: - Methodology (baseline costs, included/excluded items) - Sample size or number of programs supporting the figures - Customer names tied to reported metrics Recommendation: buyers should request: - At least two to three customer references in similar therapeutic areas - A sample KPI dashboard and engagement reporting pack - A redacted SOW example and staffing plan

04Best fit

Company size

Based on public headcount estimates, Epikast appears to operate as a small team and is oriented toward:

Small to mid-sized biopharma companies that are commercial-stage or preparing for launch
Targeted programs inside larger pharma where a flexible external team or pod is preferred

Suggested ICP (practical buying hypothesis):

Organizations with approximately 50–2,000 employees in biopharma/biotech, particularly with lean commercial or medical affairs teams
Buyers that need to stand up MSL coverage, reimbursement support, patient services hubs, or hybrid sales quickly

Based on public headcount estimates, Epikast appears to operate as a small team and is oriented toward: - Small to mid-sized biopharma companies that are commercial-stage or preparing for launch - Targeted programs inside larger pharma where a flexible external team or pod is preferred Suggested ICP (practical buying hypothesis): - Organizations with approximately 50–2,000 employees in biopharma/biotech, particularly with lean commercial or medical affairs teams - Buyers that need to stand up MSL coverage, reimbursement support, patient services hubs, or hybrid sales quickly

Industries and verticals

Biopharmaceutical companies
Medtech
Payers and insurers

Roles and personas

Decision makers:

VP/SVP Commercial, Head of Sales
VP Medical Affairs, Field Medical leadership
Head of Market Access / Reimbursement
Head of Patient Services / Patient Support
Compliance, Legal, and Regulatory stakeholders

End users:

MSLs, sales representatives, patient case managers
Operations analysts and brand teams consuming insights

05The pitch

What the product does (objective value proposition)

Key stated outcomes and vendor claims (not independently validated):

Vendor-claimed cost savings versus older models, while scaling HCP/patient outreach.
Vendor-claimed "launch-ready in 2–3 months" via trained teams that can integrate into client workflows.

These are vendor claims; Epikast does not publish independent validation, methodology, or standardized benchmarking for the cost-savings figures.

Epikast is a life-sciences services and technology provider that supplies medically credentialed commercial and medical-affairs personnel (for example, remote/field sales representatives, MSLs, reimbursement specialists, patient coordinators/case managers) and supplements that workforce with AI-supported engagement and analytics tools. The company positions itself as an alternative to traditional field-heavy commercialization and engagement models and seeks to increase stakeholder coverage and reduce operational costs via a hybrid delivery model and a Greece-based talent hub supporting US and European stakeholder interactions. Key stated outcomes and vendor claims (not independently validated): - Vendor-claimed cost savings versus older models, while scaling HCP/patient outreach. - Vendor-claimed "launch-ready in 2–3 months" via trained teams that can integrate into client workflows. These are vendor claims; Epikast does not publish independent validation, methodology, or standardized benchmarking for the cost-savings figures.

Target market and market positioning

Epikast targets:

Commercial leaders at biopharma (organizations with constrained budgets or HCP access challenges)
Medical Affairs teams (scientific exchange, compliant engagement, pre- and post-launch activities)
Patient Services leaders (hub/case management, treatment initiation and adherence)
Payers/insurers (member support)

Positioning: the vendor describes itself as a hybrid engagement provider combining credentialed talent and internal AI-supported tooling, with an emphasis on peer-level scientific engagement and compliance.

Epikast targets: - Commercial leaders at biopharma (organizations with constrained budgets or HCP access challenges) - Medical Affairs teams (scientific exchange, compliant engagement, pre- and post-launch activities) - Patient Services leaders (hub/case management, treatment initiation and adherence) - Payers/insurers (member support) Positioning: the vendor describes itself as a hybrid engagement provider combining credentialed talent and internal AI-supported tooling, with an emphasis on peer-level scientific engagement and compliance.

Get a comprehensive analysis of Epikast including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →